There is a need to determine the conditions that will maximize the capacity of adult and neonatal islets to function as a viable graft in diabetic animals. Central to viability in avascular pancreatic grafts is revascularization. Therefore the primary aim of this project is to assess the role of basic fibroblast growth factor (FGF), an angiogenic protein, in pancreatic islet transplantation into normal and diabetic rats. This would be the first attempt to use this peptide, the most potent angiogenic mediator yet isolated, to promote revascularization. The hypothesis for this approach is that angiogenic mediators should significantly enhance graft performance. This hypothesis will be tested by showing the effects of FGF on islet blood flow, islet growth, and function in transplantation experiments. The expected beneficial effects of increased vascularization by FGF might be reflected in a substantial decrease in the number of neonatal or adult islets needed to cure diabetes.
The specific aims are: 1. To assess the effects of FGF in islet transplantation into normal rats on a) islet blood flow; b) islet growth; and c) islet function. 2. To assess the effects of FGF on islets transplanted into diabetic and insulin-treated diabetic rats. 3. To determine whether FGF lessens the number of transplanted adult or neonatal islets needed to cure experimental diabetes. Success with the use of exogenous angiogenic mediators will be measured by their ability to enhance function and to decrease the amount of purified endocrine replacement tissue needed for transplantation into diabetic recipients. Positive results in these experiments should be important to human diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK039087-03
Application #
3238782
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1988-12-01
Project End
1992-11-30
Budget Start
1990-12-01
Budget End
1992-11-30
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Whittier Institute for Diabetes & Endoc
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Beattie, G M; Lopez, A D; Otonkoski, T et al. (1999) Transplantation of human fetal pancreas: fresh vs. cultured fetal islets or ICCS. J Mol Med 77:70-3
Cirulli, V; Crisa, L; Beattie, G M et al. (1998) KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 140:1519-34
Wang, S; Beattie, G M; Mally, M I et al. (1997) Isolation and characterization of a cell line from the epithelial cells of the human fetal pancreas. Cell Transplant 6:59-67
Wang, S; Beattie, G M; Hayek, A et al. (1996) Development of a VSV-G protein pseudotyped retroviral vector system expressing dominant oncogenes from a lacO-modified inducible LTR promoter. Gene 182:145-50
Beattie, G M; Rubin, J S; Mally, M I et al. (1996) Regulation of proliferation and differentiation of human fetal pancreatic islet cells by extracellular matrix, hepatocyte growth factor, and cell-cell contact. Diabetes 45:1223-8
Otonkoski, T; Cirulli, V; Beattie, M et al. (1996) A role for hepatocyte growth factor/scatter factor in fetal mesenchyme-induced pancreatic beta-cell growth. Endocrinology 137:3131-9
Mally, M I; Cirulli, V; Hayek, A et al. (1996) ICA69 is expressed equally in the human endocrine and exocrine pancreas. Diabetologia 39:474-80
Itkin-Ansari, P; Bain, G; Beattie, G M et al. (1996) E2A gene products are not required for insulin gene expression. Endocrinology 137:3540-3
Mally, M I; Cirulli, V; Otonkoski, T et al. (1996) Ontogeny and tissue distribution of human GAD expression. Diabetes 45:496-501
Otonkoski, T; Hayek, A (1995) Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. J Clin Endocrinol Metab 80:3779-83

Showing the most recent 10 out of 30 publications